<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>dividend yield on FinanClub</title>
    <link>https://finan.club/tags/dividend-yield/</link>
    <description>Recent content in dividend yield on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Sat, 12 Aug 2023 06:29:37 +0000</lastBuildDate><atom:link href="https://finan.club/tags/dividend-yield/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>AGNC</title>
      <link>https://finan.club/us/agnc/</link>
      <pubDate>Sat, 12 Aug 2023 06:29:37 +0000</pubDate>
      
      <guid>https://finan.club/us/agnc/</guid>
      <description>score:935
Chances: Highlighting AGNC Investment Corp. as one of the best monthly dividend stocks to buy according to analysts. Exploring high-yield dividend stocks with an average yield of almost 11.1% and their potential for consistent income. Announcing AGNC&amp;rsquo;s declaration of a cash dividend of $0.</description>
    </item>
    
    <item>
      <title>GGB</title>
      <link>https://finan.club/us/ggb/</link>
      <pubDate>Sat, 12 Aug 2023 06:26:18 +0000</pubDate>
      
      <guid>https://finan.club/us/ggb/</guid>
      <description>score:178
Chances: Gerdau&amp;rsquo;s stock has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company&amp;rsquo;s earnings prospects, which could drive the stock higher in the near term. Stocks like GGB are attracting investor attention due to their higher dividend yields compared to the industry.</description>
    </item>
    
    <item>
      <title>PFE</title>
      <link>https://finan.club/us/pfe/</link>
      <pubDate>Sat, 12 Aug 2023 05:38:00 +0000</pubDate>
      
      <guid>https://finan.club/us/pfe/</guid>
      <description>score:-15
Chances: Strong earnings and revenue beat ratios for the healthcare sector. Attractive dividend yield of 4.7%, making it appealing for income-seeking investors. Global presence and strong fundamentals of Pfizer as a pharmaceutical heavyweight. Risks: Challenges related to declining sales of Covid products.</description>
    </item>
    
  </channel>
</rss>
